开发基质独立的肝素涂层,以减轻表面诱导的血栓形成:疗效和机制
Shengjun Cheng1, Haifeng Ji1, Tao Xu1
1College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610065, People's Republic of China. 903699293@qq.com.
Journal of materials chemistry. B
|October 1, 2024
概括
一种新的,用于医疗器械的快速氨酸涂层可以防止血栓形成,而不会增加出血风险. 这种简单的方法增强了血液兼容性,使血液治疗更安全.
科学领域:
- 生物材料科学 生物材料科学
- 表面化学 表面化学
- 血液静止 血液静止 血液静止
背景情况:
- 血液接触材料上的氨酸涂层减少了抗凝剂的需求,但通常涉及复杂的预修,并且可以过度抑制凝血,冒着出血的风险.
- 氨酸涂层的现有方法可能耗时,可能导致意外的全身抗凝,危及患者的安全.
研究的目的:
- 开发一种简单的,基质独立的肝素涂层,具有改善的血液兼容性和受控的抗凝剂机制.
- 研究新的肝素涂层的机制,以确保预防血栓形成,而不会增加出血风险.
主要方法:
- 多巴胺/奇托桑的同时沉积,随后是氨酸的静电结合,在1小时内实现了涂层.
- 使用血再化时间 (PRT) 评估抗凝剂活性,并通过血液溶解,血小板粘附/激活和纤维原粘附评估血红相容性.
主要成果:
- 形成的涂层显著延长了PRT (>60分钟),表明有效预防表面诱导的血栓形成.
- 证明了有利的血红相容性,血液溶解比率<2%,血小板粘附/激活最小,纤维原粘附低.
- 系统地阐明了抗凝剂机制,证实了血栓形成的预防而不影响血静.
结论:
- 通过多巴胺/基托共同沉积,快速,基质独立的肝素涂层为血液接触材料提供了一个有前途的解决方案.
- 涂层提供有效的抗凝和血液相容性,解决了以前方法的局限性,并支持临床可行性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Extrinsic and Intrinsic Pathways of Hemostasis
6.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.3K
Formation of the Platelet Plug
5.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.1K


